skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Nucleic acids encoding HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations

Patent ·
OSTI ID:1892576
; ; ; ; ; ;

The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.

Research Organization:
Argonne National Laboratory (ANL), Argonne, IL (United States)
Sponsoring Organization:
USDOE; National Institutes of Health (NIH)
DOE Contract Number:
AC02-06CH11357; AI084817; AI100663; AI110657; GM094586
Assignee:
The Scripps Research Institute (Village of La Jolla, CA)
Patent Number(s):
11,236,134
Application Number:
16/780,495
OSTI ID:
1892576
Resource Relation:
Patent File Date: 02/03/2020
Country of Publication:
United States
Language:
English

References (22)

Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env journal March 2015
Alteration of immune response using pan DR-binding peptides patent April 1998
Recombinant HIV-1 Envelope Proteins and Their Use patent-application August 2017
Highly Stable Trimers Formed by Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Fused with the Trimeric Motif of T4 Bacteriophage Fibritin journal May 2002
Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity journal September 2015
A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies journal September 2013
Novel HIV-1 Envelope Glycoprotein patent-application July 2014
Variable-Loop-Deleted Variants of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Can Be Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits journal January 2000
Stabilized mosaic human immunodeficiency virus type 1 (HIV-1) GP140 envelope (ENV) trimers patent April 2018
Stabilizing the Native Trimer of HIV-1 Env by Destabilizing the Heterodimeric Interface of the gp41 Postfusion Six-Helix Bundle journal June 2014
Structure-Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers journal December 2015
Cleavage-Independent HIV-1 Env Trimers Engineered as Soluble Native Spike Mimetics for Vaccine Design journal April 2015
Self-assembling peptide nanoparticles useful as vaccines patent October 2013
Modifications That Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Trimers in Solution journal May 2000
Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation journal October 2013
Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors journal March 2013
Mutations That Destabilize the gp41 Core Are Determinants for Stabilizing the Simian Immunodeficiency Virus-CPmac Envelope Glycoprotein Complex journal April 2002
The Structure of Docking Domains in Modular Polyketide Synthases journal August 2003
Alanine Scanning Mutagenesis of HIV-1 gp41 Heptad Repeat 1: Insight into the gp120−gp41 Interaction journal May 2010
Structural Mechanism of Trimeric HIV-1 Envelope Glycoprotein Activation journal July 2012
Methods for Generating Stably Linked Complexes Composed of Homodimers, Homotetramers or Dimers of Dimers and Uses patent-application October 2006
Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice journal May 2014

Similar Records

Related Subjects